Selective glucocorticoid receptor modulators: Future of glucocorticoid immunosuppressive therapy?

Endocrinology

Volumn 152, Issue 8, 2011, Pages 2927-2929

  Quax, R A M ^a   Peeters, R P ^a   Feelders, R A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; SELECTIVE GLUCOCORTICOID RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

DIABETES MELLITUS; DNA POLYMORPHISM; DRUG MECHANISM; DRUG SENSITIVITY; GLUCONEOGENESIS; GLUCOSE TOLERANCE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; MUSCLE ATROPHY; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SHORT SURVEY; SIDE EFFECT; TRANSACTIVATION; TRANSCRIPTION REGULATION; WEIGHT GAIN;

GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RECEPTORS, GLUCOCORTICOID;

EID: 79960729433     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2011-1258     Document Type: Short Survey

References (30)

1. Barahona MJ, Sucunza N, Resmini E, Fernández-Real JM, Ricart W, Moreno-Navarrete JM, Puig T, Farrerons J, Webb SM 2009 Persistent body fat mass and inflammatory marker increases after longterm cure of Cushing's syndrome. J Clin Endocrinol Metab 94:3365-3371
2. Barahona MJ, Sucunza N, Resmini E, Fernández-Real JM, Ricart W, Moreno-Navarrete JM, Puig T, Wägner AM, Rodriguez-Espinosa J, Farrerons J, Webb SM 2009 Deleterious effects of glucocorticoid replacement on bone in women after long-term remission of Cushing's syndrome. J Bone Miner Res 24:1841-1846
3. Webb SM, Badia X, Barahona MJ, Colao A, Strasburger CJ, Tabarin A, van Aken MO, Pivonello R, Stalla G, Lamberts SW, Glusman JE 2008 Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire. Eur J Endocrinol 158:623-630 (Pubitemid 351639599)
4. Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D, Filippella M, Marzullo P, Cerbone G, Siciliani M, Lombardi G 1999 Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab 84:2664-2672 (Pubitemid 30641990)
5. Dekkers OM, Biermasz NR, Pereira AM, Roelfsema F, van Aken MO, Voormolen JH, Romijn JA 2007 Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 92:976-981 (Pubitemid 46465672)
6. Hudson AR, Roach SL, Higuchi RI 2008 Recent developments in the discovery of selective glucocorticoid receptor modulators (SGRMs). Curr Top Med Chem 8:750-765 (Pubitemid 351982564)
7. De Bosscher K, Haegeman G, Elewaut D 2010 Targeting inflammation using selective glucocorticoid receptor modulators. Curr Opin Pharmacol 10:497-504
8. De Bosscher K 2010 Selective glucocorticoid receptor modulators. J Steroid Biochem Mol Biol 120:96-104
9. Schäcke H, Schottelius A, Döcke WD, Strehlke P, Jaroch S, Schmees N, Rehwinkel H, Hennekes H, Asadullah K 2004 Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA 101:227-232 (Pubitemid 38084232)
10. Vayssière BM, Dupont S, Choquart A, Petit F, Garcia T, Marchandeau C, Gronemeyer H, Resche-Rigon M 1997 Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol 11:1245-1255 (Pubitemid 28041332)
11. De Bosscher K, Vanden Berghe W, Haegeman G 2003 The interplay between the glucocorticoid receptor and nuclear factor-κB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev 24:488-522 (Pubitemid 37059110)
12. Kumar R, Thompson EB 2005 Gene regulation by the glucocorticoid receptor: structure:function relationship. J Steroid Biochem Mol Biol 94:383-394 (Pubitemid 40616400)
13. Payne DN, Adcock IM 2001 Molecular mechanisms of corticosteroid actions. Paediatr Respir Rev 2:145-150 (Pubitemid 32694560)
14. Reichardt HM, Schütz G 1998 Glucocorticoid signalling-multiple variations of a common theme. Mol Cell Endocrinol 146:1-6 (Pubitemid 29003274)
15. Ito K, Barnes PJ, Adcock IM 2000 Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1β-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol 20:6891-6903
16. van Raalte DH, Ouwens DM, Diamant M 2009 Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest 39:81-93
17. Tomlinson JJ, Boudreau A, Wu D, Atlas E, Haché RJ 2006 Modulation of early human preadipocyte differentiation by glucocorticoids. Endocrinology 147:5284-5293 (Pubitemid 44790583)
18. Rauch A, Gossye V, Bracke D, Gevaert E, Jacques P, Van Beneden K, Vandooren B, Rauner M, Hofbauer LC, Haegeman G, Elewaut D, Tuckermann JP, De Bosscher K 2011 An anti-inflammatory selective glucocorticoid receptor modulator preserves osteoblast differentiation. FASEB J 25:1323-1332
19. Ayroldi E, Migliorati G, Bruscoli S, Marchetti C, Zollo O, Cannarile L, D'Adamio F, Riccardi C 2001 Modulation of T-cell activation by the glucocorticoid-induced leucine zipper factor via inhibition of nuclear factor κB. Blood 98:743-753
20. Barnes PJ 2006 Corticosteroid effects on cell signalling. Eur Respir J 27:413-426 (Pubitemid 43185854)
21. Chikanza LC, Panayi GS 1993 The effects of hydrocortisone on in vitro lymphocyte proliferation and interleukin-2 and -4 production in corticosteroid sensitive and resistant subjects. Eur J Clin Invest 23:845-850 (Pubitemid 24015628)
22. Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, Jewell DP 1996 Predicting outcome in severe ulcerative colitis. Gut 38:905-910 (Pubitemid 26231777)
23. Barnes PJ 2011 Glucocorticosteroids: current and future directions. Br J Pharmacol 163:29-43
24. van Oosten MJ, Dolhain RJ, Koper JW, van Rossum EF, Emonts M, Han KH, Wouters JM, Hazes JM, Lamberts SW, Feelders RA 2010 Polymorphisms in the glucocorticoid receptor gene that modulate glucocorticoid sensitivity are associated with rheumatoid arthritis. Arthritis Res Ther 12:R159
25. Barnes PJ, Adcock IM 2009 Glucocorticoid resistance in inflammatory diseases. Lancet 373:1905-1917
26. Silverman MN, Sternberg EM 2008 Neuroendocrine-immune interactions in rheumatoid arthritis: mechanisms of glucocorticoid resistance. Neuroimmunomodulation 15:19-28
27. Hearing SD, Norman M, Probert CS, Haslam N, Dayan CM 1999 Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes. Gut 45:382-388 (Pubitemid 29400714)
28. Corrigan CJ, Brown PH, Barnes NC, Szefler SJ, Tsai JJ, Frew AJ, Kay AB 1991 Glucocorticoid resistance in chronic asthma. Glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral blood T cell proliferation by glucocorticoids in vitro. Am Rev Respir Dis 144:1016-1025
29. Smit P, Russcher H, de Jong FH, Brinkmann AO, Lamberts SW, Koper JW 2005 Differential regulation of synthetic glucocorticoids on gene expression levels of glucocorticoid-induced leucine zipper and interleukin-2. J Clin Endocrinol Metab 90:2994-3000 (Pubitemid 40686355)
30. Hu X, Du S, Tunca C, Braden T, Long KR, Lee J, Webb EG, Dietz JD, Hummert S, Rouw S, Hegde SG, Webber RK, and Obukowicz MG 2011 The antagonists but not partial agonists of glucocorticoid receptor ligands show substantial side effect dissociation Endocrinology 152:3123-3134